Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC101 TIL in advanced melanoma
NCT06120712Phase 2Completed
- Sponsor
- Juncell Therapeutics
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nolgileucel in melanoma, sponsored by Juncell Therapeutics. Primary endpoints: Adverse Events at 28 days and Objective Response Rate at 90 days. Started Nov 2023; status: completed.
02
Drugs
nolgileucel
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06120712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06120712.